Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ITGAL | P20701 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497734 | 1.00 | RAB9A (0.53) | RAB9AALDH1A1SMN1; SMN2GAAITGAL | |
| SCHEMBL6503990 | 0.92 | CAPN1 (0.45) | RAB9AALDH1A1SMN1; SMN2GAAITGAL | |
| SCHEMBL6503994 | 0.92 | CAPN1 (0.45) | RAB9AALDH1A1SMN1; SMN2GAAITGAL | |
| SCHEMBL6504675 | 0.88 | CAPN1 (0.43) | RAB9AALDH1A1SMN1; SMN2ITGALENPP2 | |
| SCHEMBL6504678 | 0.88 | CAPN1 (0.43) | RAB9AALDH1A1SMN1; SMN2ITGALENPP2 | |
| SCHEMBL6503636 | 0.87 | ITGAL (0.51) | RAB9AALDH1A1SMN1; SMN2ITGALCAPN1 | |
| SCHEMBL6503640 | 0.87 | ITGAL (0.51) | RAB9AALDH1A1SMN1; SMN2ITGALCAPN1 | |
| SCHEMBL8297134 | 0.87 | ITGAL (0.51) | RAB9AALDH1A1SMN1; SMN2ITGALCAPN1 | |
| SCHEMBL6495775 | 0.85 | ITGAL (0.49) | RAB9ASMN1; SMN2ITGALENPP2CAPN1 | |
| SCHEMBL6495771 | 0.85 | ITGAL (0.49) | RAB9ASMN1; SMN2ITGALENPP2CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | RAB9A 2089/4885ALDH1A1 2202/4885SMN1; SMN2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.